Biotech Values

[biotech jim]

The oral delivery of proteins data by Protalix looks reasonable to me.

I have not followed Protalix, but I did look at the slides, from 49 and beyond showing the relevant data. The data set is substantial and significant for the initial proof of concept. I will look into this further, but to me some initial questions would be:

1. What is the amount of cellular plant material given to result in efficacious ERT enxyme levels in blood.

2. What is the toxicology path as directed by the FDA for this type of oral material?

3. In primates, has any sensitization seen to date for the ingested materials upon multiple repeat dosings over a substantial time period?


I do know Roche has some different technology ongoing to address the oral delivery problem also.